KR20130141474A - 쓴맛을 나타내는 약물을 함유하는 과립 및 구강내 붕괴정 - Google Patents

쓴맛을 나타내는 약물을 함유하는 과립 및 구강내 붕괴정 Download PDF

Info

Publication number
KR20130141474A
KR20130141474A KR1020137008136A KR20137008136A KR20130141474A KR 20130141474 A KR20130141474 A KR 20130141474A KR 1020137008136 A KR1020137008136 A KR 1020137008136A KR 20137008136 A KR20137008136 A KR 20137008136A KR 20130141474 A KR20130141474 A KR 20130141474A
Authority
KR
South Korea
Prior art keywords
copolymer
drug
methacrylic acid
methyl
granules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137008136A
Other languages
English (en)
Korean (ko)
Inventor
유지 미야모토
다쿠야 도쿠다
모토히로 오타
야스히로 이시카와
Original Assignee
교와 핫꼬 기린 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 교와 핫꼬 기린 가부시키가이샤 filed Critical 교와 핫꼬 기린 가부시키가이샤
Publication of KR20130141474A publication Critical patent/KR20130141474A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020137008136A 2010-08-31 2011-04-08 쓴맛을 나타내는 약물을 함유하는 과립 및 구강내 붕괴정 Ceased KR20130141474A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010194755 2010-08-31
JPJP-P-2010-194755 2010-08-31
PCT/JP2011/058919 WO2012029348A1 (ja) 2010-08-31 2011-04-08 苦味を呈する薬物を含有する顆粒および口腔内崩壊錠

Publications (1)

Publication Number Publication Date
KR20130141474A true KR20130141474A (ko) 2013-12-26

Family

ID=43950218

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137008136A Ceased KR20130141474A (ko) 2010-08-31 2011-04-08 쓴맛을 나타내는 약물을 함유하는 과립 및 구강내 붕괴정

Country Status (5)

Country Link
US (1) US20130224295A1 (https=)
EP (1) EP2614816A4 (https=)
JP (2) JP4803686B2 (https=)
KR (1) KR20130141474A (https=)
WO (1) WO2012029348A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180039492A (ko) * 2016-10-10 2018-04-18 한미약품 주식회사 고미 및 이물감이 개선된 에르도스테인 과립제제
WO2020017808A1 (ko) * 2018-07-16 2020-01-23 연성정밀화학(주) 날푸라핀 함유 구강붕해정

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2612657B1 (en) * 2010-08-31 2023-08-09 Kyowa Kirin Co., Ltd. Orodispersible tablet
JP5690925B2 (ja) * 2011-04-28 2015-03-25 持田製薬株式会社 口腔内崩壊性に優れたコーティング組成物
JP5940530B2 (ja) * 2011-06-17 2016-06-29 株式会社三和化学研究所 ポリスチレンスルホン酸塩含有医薬製剤
JP5756727B2 (ja) * 2011-09-30 2015-07-29 ハウス食品グループ本社株式会社 顆粒
JP6040218B2 (ja) * 2012-02-23 2016-12-07 フロイント産業株式会社 口腔内崩壊錠用直打賦形剤及びその製造方法、並びに口腔内崩壊錠
JP6004702B2 (ja) * 2012-03-30 2016-10-12 小林製薬株式会社 不快味が軽減された固形製剤の製造方法
FI126168B (en) 2012-09-18 2016-07-29 Novaldmedical Ltd Oy A method for coating pharmaceutical substrates
JP6012373B2 (ja) * 2012-09-28 2016-10-25 杏林製薬株式会社 口腔内崩壊錠
KR101352689B1 (ko) * 2012-12-31 2014-01-17 (주) 에프엔지리서치 불연속상과 연속상으로 이루어지는 응집단위를 포함하는 마이크로그래뉼 제형
KR101340733B1 (ko) 2012-12-31 2013-12-12 (주) 에프엔지리서치 신규한 마이크로그래뉼 제형
JP5836980B2 (ja) 2013-01-11 2015-12-24 信越化学工業株式会社 薬物含有粒子、固形製剤及び薬物含有粒子の製造方法
WO2014157137A1 (ja) * 2013-03-26 2014-10-02 キッセイ薬品工業株式会社 シロドシンの苦味をマスキングした経口投与製剤
KR101610894B1 (ko) 2014-05-08 2016-04-08 (주) 네추럴웨이 맛이 차폐된 비타민 c 과립
JP6147711B2 (ja) * 2014-05-26 2017-06-14 富士フイルム株式会社 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法
WO2017115764A1 (ja) * 2015-12-28 2017-07-06 日本新薬株式会社 圧縮成型製剤
EP3419659A1 (en) 2016-02-23 2019-01-02 The Regents of the University of Colorado, A Body Corporate Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens
EP3241549A1 (en) * 2016-05-02 2017-11-08 Sun Pharmaceutical Industries Limited Sprinkle composition of cinacalcet
JP6778051B2 (ja) * 2016-08-18 2020-10-28 沢井製薬株式会社 オセルタミビルリン酸塩含有医薬組成物
JP7057286B2 (ja) * 2016-12-28 2022-04-19 富士フイルム富山化学株式会社 医薬組成物
JP7182356B2 (ja) * 2017-07-05 2022-12-02 日本ケミファ株式会社 口腔内崩壊錠及びその製造方法
WO2019039420A1 (ja) 2017-08-21 2019-02-28 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
TWI795462B (zh) * 2017-11-17 2023-03-11 日商鹽野義製藥股份有限公司 光安定性及溶出性優異的醫藥製劑
EP3740197A4 (en) 2018-01-16 2021-11-10 Applied Materials, Inc. METAL OXIDE ENCAPSULATED COMPOSITIONS OF THE ACTIVE SUBSTANCE AND PROCESS FOR THEIR MANUFACTURING
CN112566635A (zh) * 2018-08-10 2021-03-26 日本脏器制药株式会社 粒状组合物及其制造方法
CN110882223A (zh) * 2018-09-11 2020-03-17 海南中济医药科技有限公司 直接压片的盐酸奥洛他定片剂配方
KR20220051385A (ko) 2019-08-27 2022-04-26 어플라이드 머티어리얼스, 인코포레이티드 약제 용해도 조절을 위한 증기상 코팅들
CN113041231B (zh) * 2019-12-26 2024-03-26 鲁南制药集团股份有限公司 一种替比培南酯细粒剂组合物及其制备方法
TWI870622B (zh) 2020-10-02 2025-01-21 美商應用材料股份有限公司 製備氧化矽塗佈藥品的低溫處理
EP4408402A4 (en) 2021-09-30 2025-08-06 Applied Materials Inc LOW TEMPERATURE SILICON OXIDE COATING FOR PHARMACEUTICAL APPLICATIONS
GB2643925A (en) 2024-09-09 2026-03-11 Novumgen Ltd An orodispersible tablet of topiramate and its process of preparation
CN120360958B (zh) * 2025-05-27 2025-10-28 江苏和汇医药科技有限公司 一种奥洛他定口腔快速崩解片组合物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
ATE432692T1 (de) * 2001-03-06 2009-06-15 Kyowa Hakko Kirin Co Ltd Tabletten, die in der mundhöhle schnell zerfallen
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
JP2007501810A (ja) * 2003-08-11 2007-02-01 メルク フロスト カナダ リミテツド 一段階被覆法を用いて作製された着香味遮蔽製薬製剤
US8153161B2 (en) * 2003-12-09 2012-04-10 Dainippon Sumitomo Pharma Co., Ltd. Medicament-containing particle and a solid preparation containing the particle
US8663694B2 (en) * 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
KR101314439B1 (ko) * 2005-05-20 2013-10-07 다이이찌 산쿄 가부시키가이샤 덱스트로오스 함유 필름 코팅 제제
JP4439499B2 (ja) * 2005-08-01 2010-03-24 大日本住友製薬株式会社 アムロジピン含有粒子およびそれからなる口腔内崩壊錠
US20070134493A1 (en) * 2005-12-08 2007-06-14 Kanji Meghpara Compositions and capsules with stable hydrophilic layers
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
JP2008013480A (ja) * 2006-07-05 2008-01-24 Sawai Pharmaceutical Co Ltd 薬物含有微粒子およびその製造方法
WO2008013084A1 (fr) * 2006-07-25 2008-01-31 Kowa Company, Ltd. Préparation enrobée de sucre et son procédé de fabrication
JP2008050324A (ja) * 2006-08-28 2008-03-06 Ohara Yakuhin Kogyo Kk 苦味遮蔽組成物。
JP5405752B2 (ja) * 2007-01-31 2014-02-05 大日本住友製薬株式会社 被覆された薬物含有粒子および該粒子を含む固形製剤
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
JP2009114113A (ja) * 2007-11-06 2009-05-28 Nipro Corp 口腔内崩壊錠及びその製造方法
WO2009078034A2 (en) * 2007-11-26 2009-06-25 Rubicon Research Private Limited Oral disintegrating tablets of ropinirole hydrochloride
CN102223880B (zh) * 2008-11-25 2017-04-26 田边三菱制药株式会社 口腔速崩片及其制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180039492A (ko) * 2016-10-10 2018-04-18 한미약품 주식회사 고미 및 이물감이 개선된 에르도스테인 과립제제
WO2020017808A1 (ko) * 2018-07-16 2020-01-23 연성정밀화학(주) 날푸라핀 함유 구강붕해정

Also Published As

Publication number Publication date
JP2011063627A (ja) 2011-03-31
WO2012029348A1 (ja) 2012-03-08
US20130224295A1 (en) 2013-08-29
EP2614816A4 (en) 2014-06-25
JP4803686B2 (ja) 2011-10-26
EP2614816A1 (en) 2013-07-17
JP5752132B2 (ja) 2015-07-22
JPWO2012029348A1 (ja) 2013-10-28

Similar Documents

Publication Publication Date Title
KR20130141474A (ko) 쓴맛을 나타내는 약물을 함유하는 과립 및 구강내 붕괴정
ES2739888T3 (es) Composiciones y comprimidos farmacéuticos con recubrimiento compresible y métodos de fabricación
CA2563440C (en) Orally disintegrating tablets and methods of manufacture
TWI572371B (zh) 口腔內崩壞錠及其製造方法
JP2025100927A (ja) シロドシンの苦味をマスキングした経口投与製剤
JP2013241462A (ja) ラモトリジンの口腔内崩壊錠組成物
JP6810688B2 (ja) 二重味覚マスキング技術を有する活性物質の顆粒、その生産のための方法、およびそれを含有する口内分散性錠剤
WO2001072285A1 (en) Easy-to-take granule
JP5995284B2 (ja) 固形製剤
JP5228359B2 (ja) 主薬粒子及びその製造方法ならびに口腔内崩壊錠
KR20180098282A (ko) 압축 성형 제제
JP6133009B2 (ja) トピラマート顆粒
JP5405752B2 (ja) 被覆された薬物含有粒子および該粒子を含む固形製剤
JP2003119122A (ja) 口腔内速崩壊錠およびその製造法
KR20060032628A (ko) 아미술프라이드를 포함하는 신규 고형 제약 조성물
EP2612657B1 (en) Orodispersible tablet
WO2016139683A2 (en) Pharmaceutical compositions of lurasidone and process for preparing the same
WO2009014372A2 (en) Dispersible tablet comprising coated drug-containing particles and method for the preparation thereof
WO2020213589A1 (ja) 錠剤及び錠剤の製造方法
WO2019098327A1 (ja) 速溶性薬物の苦味が抑制された口腔内崩壊錠
JP5478170B2 (ja) 口腔内崩壊錠
Patel et al. Formulation design and optimization of tastemasked mouth-dissolving tablets of Tramadol hydrochloride
JP4575717B2 (ja) アンピロキシカム含有医薬組成物とその安定化方法及びその製造方法
JP7308022B2 (ja) 速溶性薬物の苦味が抑制された口腔内崩壊錠
JP6150564B2 (ja) 口腔内速崩壊性錠剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130329

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151210

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161007

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170816

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161007

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170816

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170406

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20151210

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20130402

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20171017

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170915

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170816

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170406

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20161007

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20151210

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20130402

X601 Decision of rejection after re-examination